SPRY vs SRZN

ARS Pharmaceuticals, Inc. vs Surrozen, Inc. — Valuation Comparison 2026

SPRY

Biotechnology
ARS Pharmaceuticals, Inc.
Quality
4.7
out of 10
Value Trap
24
SAFE
Price
$9.40
Last close
Models
8/13
Active
VS

SRZN

Biotechnology
Surrozen, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$26.16
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType SPRY Fair ValueSPRY Upside SRZN Fair ValueSRZN Upside
Bayesian DCF Intrinsic $2.27 -75.8% $11.85 -54.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.53 -83.7% $3.60 -89.0%
Dynamic NAV Asset-Based $0.88 -97.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SPRY vs SRZN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SPRY vs SRZN — Which Stock Is More Undervalued?

SPRY scores higher with a 4.7/10 quality rating vs SRZN's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ARS Pharmaceuticals, Inc. (SPRY) and Surrozen, Inc. (SRZN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SPRY currently trades at $9.40 with a QOC of 4.7/10, while SRZN trades at $26.16 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).